Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

List of Essential Medicines Lebanon 2018


Foreword
 
Essential medicines as defined by the World Health Organization (WHO) are “those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility”.
 
The WHO Model list of Essential Medicines revised every two years provides a template and serves as a guide for countries to prepare their own lists taking into consideration local priorities.

Based on the current version of the WHO Model List of Essential medicines 20th edition published in 2017, the Ministry of Public Health in Lebanon through the Quality Assurance of Pharmaceutical Products Program prepared the National List of Essential Medicines EML 2018, four years after the last edition in 2014. The EML 2018 contains around 350 medicinal products and was prepared over one year by a Committee of Experts.

The EML is aligned with the National Drug Formulary and National Health Programs such as EIP Mother & Child, TB Control, HIV/AIDS, Malaria, National Mental Health Program and Primary Healthcare. The formulation and strengths of medicines listed in the EML are those mentioned under these National Health Programs and National Drug Formulary.
 
The Lebanese EML 2018 contains a core list and complementary list:

The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.
 
The list is divided into 30 sections related to the main Therapeutic classes of medicines and arranged in three columns;
 
  1. INN of the medicine,
  2. Dosage form and strength of the medicine
  3. Official Status of the medicine 
 
Medicines and dosage forms are listed in alphabetical order within each section with no implication of preference for one form over another.
 
The following symbols are used in the list to indicate the status of the medicine:
 
R: Registered drug in the Ministry of Public Health
NR: Non Registered drug in the Ministry of Public Health
HIV: included in the HIV Program
M: included in the MALARIA Program
NMHP: included in the NATIONAL MENTAL HEALTH Program
TB: included in the TUBERCULOSIS Program
U: provided through UNICEF Program
Y: provided through YMCA Program
[a]: indicates that there is an age or weight restriction on use of the medicine.
 
An index listing the Medicines by alphabetical order is available at the end of the document facilitating retrieval of information and easy reference.
 
We hope that all health providers would embrace this document as important tool for management of medicines and rationalizing prescription in the country. The EML 2018 welcomes comments from healthcare professionals; such comments help us to ensure that the National Essential medicines list remains relevant to practice.
 
The list can be accessed from the official website of the Ministry of Public Health:  www.moph.gov.lb
 

List of Essential Medicines Lebanon 2018
    3
ATC Name B/G Ingredients Dosage Form Price
A10BB12 GLUMYL 3 G Glimepiride - 3mg 3mg Tablet 511,940 L.L
A10BB12 GLYPRIDE G Glimepiride - 3mg 3mg Tablet 571,133 L.L
A10BB12 GLIM G Glimepiride - 4mg 4mg Tablet 628,918 L.L
A10BB12 GLUMYL 4 G Glimepiride - 4mg 4mg Tablet 317,403 L.L
A10BB12 GLYPRIDE G Glimepiride - 4mg 4mg Tablet 657,139 L.L
H04AA01 GLUCAGEN BioTech Glucagon HCl - 1mg 1mg Injectable powder for solution+diluent 1,343,444 L.L
B05CX01 GLUCOSE INJ. G Glucose - 10g/20ml 50% Injectable solution 5,038,066 L.L
B05CX01 GLUCOSE INJ. G Glucose - 6g/20ml 30% Injectable solution 5,157,668 L.L
D02AX GLYCERINE G Glycerol - Liquid 163,821 L.L
A03AB02 GLYCOPYRROLATE B Glycopyronium Bromide - 0.2mg/ml 0.2mg/ml Injectable solution 7,238,185 L.L
A04AA02 GRANI-DENK G Granisetron - 1mg/ml 1mg/ml Injectable concentrate for solution 893,655 L.L
A04AA02 GRANI-DENK G Granisetron - 3mg/3ml 3mg/3ml Injectable concentrate for solution 1,679,803 L.L
D01BA01 GRISEOFULVIN G Griseofulvin - 500mg 500mg Tablet, scored 575,933 L.L
C05CA54 GINKOR FORT B Heptaminol HCl - 0.300g, Troxerutine - 0.300g, Ginkgo biloba extract - 0.014g Capsule 681,328 L.L
J06BA02 GAMUNEX-C BioHuman Human normal immunoglobulin G - 10% 10% Injectable solution 39,990,287 L.L
L01EA01 GLIVEC B Imatinib (mesylate) - 100mg 100mg Tablet, film coated 48,388,666 L.L
L01EA01 GLIMATINIB BENTA G Imatinib (mesylate) - 100mg 100mg Tablet, film coated 17,619,185 L.L
L01EA01 GLIMATINIB BENTA G Imatinib (mesylate) - 100mg 100mg Tablet, film coated 43,103,200 L.L
L01EA01 GLIMATINIB BENTA 400 G Imatinib (mesylate) - 400mg 400mg Tablet, film coated 38,254,090 L.L
D06BB10 GENIMOD G Imiquimod - 5% 5% Cream 2,268,406 L.L
A10AE04 GLARTUS BioTech Insulin glargine - 100U/ml 100U/ml Injectable solution 1,346,530 L.L
C09CA04 GIZLAN G Irbesartan - 150mg 150mg Tablet, film coated 748,520 L.L
C09DA04 GIZLAN-PLUS G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C09CA04 GIZLAN G Irbesartan - 300mg 300mg Tablet, film coated 768,678 L.L
C09DA04 GIZLAN-PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C09DA04 GIZLAN-PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 25mg Tablet, film coated 768,678 L.L
A03FA GANATON B Itopride Hydrochloride - 50mg 50mg Tablet 1,119,421 L.L
A03FA GANATON B Itopride Hydrochloride - 50mg 50mg Tablet 357,462 L.L
A10BD19 GLYXAMBI B Linagliptin - 5mg, Empagliflozin - 10mg Tablet, film coated 4,162,216 L.L
A10BD19 GLYXAMBI B Linagliptin - 5mg, Empagliflozin - 10mg Tablet, film coated 4,162,216 L.L
    3
Sitemap
© Copyrights reserved to Ministry of Public Health 2025